OA-08 Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Results From a Phase 1 Study
Myo Htut(City Of Hope National Medical Center), Susan Bal(University of Alabama at Birmingham), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Tara Gregory(Colorado Blood Cancer Institute), Jesús G. Berdeja(Tennessee Oncology), Omar Nadeem(Harvard University), Thomas G. Martin(University of California San Francisco Medical Center), Michael R. Burgess(Bristol-Myers Squibb (United States)), Wei-Ming Kao(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Alok Shrestha(Bristol-Myers Squibb (United States)), Chaoqun Mei(Bristol-Myers Squibb (United States)), Luciano J. Costa(University of Alabama at Birmingham), Larry J. Anderson(United States Department of Health and Human Services), Allison Kaeding(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505